-
The Bull Thesis For Merck Is Evaporating
Monday, October 30, 2017 - 11:14amThe bullish case for Merck & Co., Inc. (NYSE: MRK) has been "derailed" after the company signaled to investors last week a longer-than-expected delay in a key lung cancer trial for its Keytruda therapy. Morgan Stanley's David Risinger downgrades Merck's stock rating from Overweight to Equal-...
Read More >> -
Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application
Monday, October 30, 2017 - 10:08amAnalysts at Barclays no longer hold a bullish view on Merck & Co., Inc. (NYSE: MRK) due to a now diminished potential for its biggest value driver, Keytruda. The firm's Geoff Meacham downgraded Merck's stock rating from Overweight to Equal Weight with a price target slashed from $72 to $62....
Read More >> -
Analyst: Entrectinib's Potential Gives Ignyta's Stock 116% Upside
Wednesday, October 18, 2017 - 11:23amAnalysts at Ladenburg Thalmann turned incrementally bullish on Ignyta Inc (NASDAQ: RXDX) after the company's therapy for the treatment of rare lung cancer showed encouraging results in a preliminary clinical trial among patients with a defective cancer-causing gene that is found in around 2...
Read More >> -
Mirati Therapeutics Sitravatinib Data, Explained
Friday, September 15, 2017 - 10:42amMirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib. The company said the data will be presented at the IASLC 2017...
Read More >> -
The Next Steps For OncoCyte After Better-Than-Expected Data
Tuesday, May 23, 2017 - 1:55pmShares of OncoCyte Corp (NYSE: OCX) were highly volatile Monday and Tuesday in reaction to the company presenting positive lung cancer blood test data to the American Thoracic Society. Keay Nakae of Chardan maintains a Buy rating on OncoCyte's stock with a price target raised from $5.50 to $7.50,...
Read More >> -
Today's Top Mover: HTG Molecular Soars 60%
Thursday, March 23, 2017 - 8:53amShares of HTG Molecular Diagnostics Inc (NASDAQ: HTGM) soared higher by more than 60 percent early Thursday morning after the molecular profiling company confirmed regulatory approval for its products in Europe. HTG Molecular announced that it has obtained CE marking in the European Union for its...
Read More >> -
Which Pharma Players Dominate The Lung Cancer Space?
Wednesday, January 25, 2017 - 3:40pmLung and bronchus cancer is the leading cause of cancer deaths in the United States, according to the National Cancer Institute. Lung cancer is of two types, namely non-small cell lung cancer, or NSCLC and small cell lung cancer, or SCLC, with the former more prevalent than the latter. Estimates by...
Read More >> -
Clovis Oncology Issues Update On Rociletinib, Will Meet With FDA On April 12
Friday, February 12, 2016 - 12:09pmClovis Oncology Inc (NASDAQ: CLVS) announced on Friday that the U.S. Food and Drug Administration has scheduled a date of April 12, 2016 to discuss a New Drug Application for its rociletinib therapy. Rociletinib is an investigational therapy for the treatment of patients with mutant epidermal...
Read More >> -
Here's Why Shares Of Onco Genex Pharma Are Plunging
Thursday, January 21, 2016 - 10:28amShares of OncoGenex Pharmaceuticals Inc (NASDAQ: OGXI), a nano-cap and clinical-stage biopharmaceutical company, were trading lower by nearly 25 percent at $0.580 early Thursday morning. OncoGenex Pharmaceuticals announced after Wednesday's market close that data from its Phase 2 Spruce trial which...
Read More >> -
EXCLUSIVE: VolitionRX CEO Talks Trial Updates, Time Until Market
Wednesday, January 6, 2016 - 10:00amVolitionRX Ltd (NYSE: VNRX) stirred up some interest in the biotech community with blood tests that can predict colon cancer. What this means is that patients may no longer have to subject themselves to an invasive colonoscopy. In an exclusive interview with Benzinga, CEO Cameron Reynolds...
Read More >>